Schizophrenia and Psychoses

Featured Article

Old Challenges and New Directions in Managing Tardive Dyskinesia

Old Challenges and New Directions in Managing Tardive Dyskinesia

"Since the current generation of psychiatrists has been raised on second-generation antipsychotics and has relatively little experience with first-generation antipsychotics, keeping tardive dyskinesia in mind is not, on the whole, part of their experience or training," said Christoph U. Correll, MD.

Latest

Moderate Association Between Sociocognitive Functioning and Thought Disorder in Schizophrenia

Moderate Association Between Sociocognitive Functioning and Thought Disorder in Schizophrenia

Interventions focused on emotion recognition may be effective in addressing sociocognitive deficits in patients with schizophrenia.

First-Episode Delusional Disorder vs Schizophrenia: Assessment of Outcomes

First-Episode Delusional Disorder vs Schizophrenia: Assessment of Outcomes

A team of UK-based investigators assessed functional and symptomatic outcomes in individuals with a first episode of psychotic disorder vs those associated with schizophrenia.

Prevalence of Schizophrenia in Individuals With Type 2 Diabetes

Prevalence of Schizophrenia in Individuals With Type 2 Diabetes

In an attempt to identify the risk associated with the comorbidity of type 2 diabetes and schizophrenia, a team of investigators from Taiwan assessed the impact of public health promotion efforts targeted at this population.

Metabolic Syndrome Predictive of Psychotic Relapse in Schizophrenia

Metabolic Syndrome Predictive of Psychotic Relapse in Schizophrenia

This research supports the monitoring of metabolic syndrome in patients with schizophrenia.

NDA Submitted for Novel Schizophrenia Treatment Lumateperone

NDA Submitted for Novel Schizophrenia Treatment Lumateperone

Lumateperone, a first-in-class molecule, works via potent interactions at 5-HT2A receptors, serotonin transporters, and D1 receptors with indirect glutamatergic modulation.

Moving Associated With Increased Risk for Psychosis in Children, Adolescents

Moving Associated With Increased Risk for Psychosis in Children, Adolescents

These data suggest that residential mobility may have a profound effect on the mental well-being of children and adolescents.

Clinical Markers Predict Resistance to Antipsychotic Therapy in Schizophrenia

Clinical Markers Predict Resistance to Antipsychotic Therapy in Schizophrenia

Timely categorization of patients as treatment-resistant or responsive may allow faster implementation of better targeted interventions.

Quetiapine Exposure Does Not Appear to Increase Risk for Infant Malformations

Quetiapine Exposure Does Not Appear to Increase Risk for Infant Malformations

In conclusion, these preliminary findings suggest that quetiapine is not a teratogen and could be used safely during pregnancy, but further research is needed to completely understand the risks involved.

Associations Between Hypovitaminosis D and Poorer Outcomes in Schizophrenia

Associations Between Hypovitaminosis D and Poorer Outcomes in Schizophrenia

Future studies should investigate how supplementation with vitamin D may improve symptoms and outcomes.

Using Neurocognitive Profiles to Predict Conversion to Psychosis in High-Risk Patients

Using Neurocognitive Profiles to Predict Conversion to Psychosis in High-Risk Patients

The study exhibited an overall conversion rate of 35% to a psychotic disorder.

Sign Up for Free e-newsletters